BRT Laboratories, Inc. Has Been Contracted By OncoMethylome Sciences, To Perform MGMT Methylation Assays for a Multi-Site, International Clinical Trial

BRT Laboratories, Inc. announced today that the laboratory has been approved by the clinical trial supporter and OncoMethylome Science's collaborator, Schering-Plough Corporation, to provide MGMT methylation testing for OncoMethylome Sciences. Starting immediately, the laboratory will be evaluating the methylation status of the MGMT gene in DNA extracted from brain tumor cells using OncoMethylome Sciences' patent-protected assay.

This is an important first step in the ongoing collaboration between BRT Laboratories, Inc. and OncoMethylome Sciences that was announced on March 29, 2006. Making this testing service available is a key milestone in OncoMethylome Sciences' collaboration with Schering-Plough, which was announced on November 11, 2005. The tumor samples will originate from the multi-center brain cancer clinical trial conducted by the U.S.-based Radiation Therapy Oncology Group (RTOG), the European Organization for Research and Treatment of Cancer (EORTC), and supported by Schering-Plough.

ABOUT BRT LABORATORIES, INC.

BRT Laboratories, Inc., a Baltimore based biotech company, is a multi-faceted laboratory offering a full range of genetic services that includes relationship analysis, identity testing, and clinical assay development. BRT has been serving the community for over 60 years in the areas of paternity, immigration, forensics, and blood donor services.